Levantinib

Nome commerciale Lenvima.
Lenvatinib acts as a multiple kinase inhibitor: It inhibits the three main vascular endothelial growth factor receptors VEGFR1, 2 and 3, as well as fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, platelet-derived growth factor receptor (PDGFR) alpha, c-Kit, and the RET proto-oncogene.

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma https://www.ncbi.nlm.nih.gov/m/pubmed/28721060/?i=4&from=Buti%20Sebastiano

https://www.tandfonline.com/doi/abs/10.1080/13543784.2018.1472235

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. https://www.ncbi.nlm.nih.gov/m/pubmed/26482279/?i=3&from=/28721060/related